{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:53:08Z","timestamp":1760575988964,"version":"build-2065373602"},"reference-count":108,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.clon.2019.07.018","type":"journal-article","created":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T07:52:05Z","timestamp":1565337125000},"page":"797-807","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cutaneous Lymphomas"],"prefix":"10.1016","volume":"31","author":[{"given":"L.","family":"Specht","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Skov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2017","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","key":"10.1016\/j.clon.2019.07.018_bib1"},{"key":"10.1016\/j.clon.2019.07.018_bib2","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/(SICI)1097-0215(19970917)72:6<923::AID-IJC1>3.0.CO;2-R","article-title":"The epidemiology of non-Hodgkin's lymphoma: comparison of nodal and extra-nodal sites","volume":"72","author":"Newton","year":"1997","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clon.2019.07.018_bib3","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.jaad.2012.02.033","article-title":"World health organization-European organization for research and treatment of cancer classification of cutaneous lymphoma in Korea: a retrospective study at a single tertiary institution","volume":"67","author":"Park","year":"2012","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.clon.2019.07.018_bib4","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1046\/j.1365-2133.2003.05476.x","article-title":"Cutaneous lymphomas other than mycosis fungoides in Singapore: a clinicopathological analysis using recent classification systems","volume":"149","author":"Tan","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clon.2019.07.018_bib5","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archderm.139.7.857","article-title":"Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clon.2019.07.018_bib6","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1001\/archderm.143.7.921","article-title":"Cutaneous T-cell lymphoid dyscrasia: a unifying term for idiopathic chronic dermatoses with persistent T-cell clones","volume":"143","author":"Guitart","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clon.2019.07.018_bib7","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1034\/j.1600-0560.2002.290801.x","article-title":"The value of molecular analysis by PCR in the diagnosis of cutaneous lymphocytic infiltrates","volume":"29","author":"Holm","year":"2002","journal-title":"J\u00a0Cutan Pathol"},{"key":"10.1016\/j.clon.2019.07.018_bib8","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2019.07.018_bib9","first-page":"1860","article-title":"Report of the Committee on Hodgkin's disease staging classification","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Res"},{"key":"10.1016\/j.clon.2019.07.018_bib10","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"year":"2010","series-title":"TNM classification of malignant tumours","author":"Sobin","key":"10.1016\/j.clon.2019.07.018_bib11"},{"key":"10.1016\/j.clon.2019.07.018_bib12","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clon.2019.07.018_bib13","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clon.2019.07.018_bib14","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1001\/archderm.143.7.854","article-title":"Incidence of cutaneous T-cell lymphoma in the United States, 1973\u20132002","volume":"143","author":"Criscione","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clon.2019.07.018_bib15","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1365-2133.2008.08852.x","article-title":"Incidence of primary cutaneous T-cell lymphoma in Norway","volume":"160","author":"Saunes","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clon.2019.07.018_bib16","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S0190-9622(99)70491-3","article-title":"Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients","volume":"40","author":"Zackheim","year":"1999","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.clon.2019.07.018_bib17","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0140-6736(08)60420-1","article-title":"Mycosis fungoides and Sezary syndrome","volume":"371","author":"Hwang","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2019.07.018_bib18","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1200\/JCO.2007.14.1374","article-title":"Analysis of primary CD30+ cutaneous lymphoproliferative disease and survival from the surveillance, epidemiology, and end results database","volume":"26","author":"Yu","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2019.07.018_bib19","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1182\/blood.V95.12.3653","article-title":"Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment","volume":"95","author":"Bekkenk","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clon.2019.07.018_bib20","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1111\/j.1365-2133.2006.07264.x","article-title":"Relative frequency and survival of patients with primary cutaneous lymphomas: data from a single-centre study of 203 patients","volume":"154","author":"Bouaziz","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clon.2019.07.018_bib21","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1365-2230.1989.tb00875.x","article-title":"Primary cutaneous follicular centre-cell lymphoma \u2013 a lymphoproliferative disease with favourable prognosis","volume":"14","author":"Pimpinelli","year":"1989","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clon.2019.07.018_bib22","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjd.17240","article-title":"British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018","volume":"180","author":"Gilson","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clon.2019.07.018_bib23","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1182\/blood-2008-04-152850","article-title":"European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas","volume":"112","author":"Senff","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clon.2019.07.018_bib24","doi-asserted-by":"crossref","first-page":"6067","DOI":"10.4081\/rt.2015.6067","article-title":"Excellent outcome of immunomodulation or Bruton's tyrosine kinase inhibition in highly refractory primary cutaneous diffuse large B-cell lymphoma, leg type","volume":"7","author":"Gupta","year":"2015","journal-title":"Rare Tumors"},{"key":"10.1016\/j.clon.2019.07.018_bib25","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/archderm.134.8.949","article-title":"Topical corticosteroids for mycosis fungoides. Experience in 79 patients","volume":"134","author":"Zackheim","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clon.2019.07.018_bib26","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/bjd.12890","article-title":"Nitrogen mustard revisited","volume":"170","author":"Knobler","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clon.2019.07.018_bib27","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/archderm.139.2.165","article-title":"Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clon.2019.07.018_bib28","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/2013.jamadermatol.541","article-title":"Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides","volume":"149","author":"Lessin","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clon.2019.07.018_bib29","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1468-3083.2011.04433.x","article-title":"Topical nitrogen mustard therapy in patients with mycosis fungoides or parapsoriasis","volume":"27","author":"Lindahl","year":"2013","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clon.2019.07.018_bib30","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1001\/archderm.138.3.325","article-title":"Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma","volume":"138","author":"Breneman","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clon.2019.07.018_bib31","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0190-9622(03)01475-0","article-title":"Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial","volume":"49","author":"Heald","year":"2003","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.clon.2019.07.018_bib32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jaad.2015.09.033","article-title":"Guidelines for phototherapy of mycosis fungoides and Sezary syndrome: a consensus statement of the United States Cutaneous Lymphoma Consortium","volume":"74","author":"Olsen","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.clon.2019.07.018_bib33","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1067\/mjd.2002.120911","article-title":"Narrowband UVB phototherapy for early-stage mycosis fungoides","volume":"47","author":"Gathers","year":"2002","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.clon.2019.07.018_bib34","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1001\/archderm.135.11.1377","article-title":"Narrowband (311-nm) UV-B therapy for small plaque parapsoriasis and early-stage mycosis fungoides","volume":"135","author":"Hofer","year":"1999","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clon.2019.07.018_bib35","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jaad.2005.03.012","article-title":"Narrowband ultraviolet B phototherapy to clear and maintain clearance in patients with mycosis fungoides","volume":"53","author":"Boztepe","year":"2005","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.clon.2019.07.018_bib36","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/1097-0142(197608)38:2<683::AID-CNCR2820380210>3.0.CO;2-V","article-title":"Oral methoxsalen photochemotherapy of mycosis fungoides","volume":"38","author":"Gilchrest","year":"1976","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2019.07.018_bib37","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/j.1365-2133.2012.11156.x","article-title":"Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB\u2013IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056)","volume":"167","author":"Whittaker","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clon.2019.07.018_bib38","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/0190-9622(95)90241-4","article-title":"Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up","volume":"33","author":"Herrmann","year":"1995","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.clon.2019.07.018_bib39","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1001\/archderm.141.3.305","article-title":"Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy","volume":"141","author":"Querfeld","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clon.2019.07.018_bib40","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/BF01930916","article-title":"Ueber den Einfluss der R\u00f6ntgenstrahlen auf die Haut in gesundem und krankem Zustande. III. Klinischer Theil","volume":"59","author":"Scholz","year":"1902","journal-title":"Archiv Dermatol Syphilis"},{"key":"10.1016\/j.clon.2019.07.018_bib41","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ijrobp.2015.01.008","article-title":"Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group","volume":"92","author":"Specht","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2019.07.018_bib42","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ijrobp.2008.06.1918","article-title":"Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas","volume":"74","author":"Neelis","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2019.07.018_bib43","doi-asserted-by":"crossref","first-page":"iv30","DOI":"10.1093\/annonc\/mdy133","article-title":"Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Willemze","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2019.07.018_bib44","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.ijrobp.2017.08.010","article-title":"Recommendations for the optimal radiation dose in patients with primary cutaneous anaplastic large cell lymphoma: a report of the Dutch Cutaneous Lymphoma Group","volume":"99","author":"Melchers","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2019.07.018_bib45","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.adro.2017.06.004","article-title":"Effectiveness of low-dose radiation for primary cutaneous anaplastic large cell lymphoma","volume":"2","author":"Smith","year":"2017","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.clon.2019.07.018_bib46","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1148\/74.4.633","article-title":"A\u00a0technique for large-field, superficial electron therapy","volume":"74","author":"Karzmark","year":"1960","journal-title":"Radiology"},{"key":"10.1016\/j.clon.2019.07.018_bib47","doi-asserted-by":"crossref","first-page":"50","DOI":"10.5114\/pdia.2013.33379","article-title":"Total skin electron irradiation techniques: a review","volume":"30","author":"Piotrowski","year":"2013","journal-title":"Postepy Dermatol Alergol"},{"key":"10.1016\/j.clon.2019.07.018_bib48","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.ijrobp.2004.02.046","article-title":"Matching the dosimetry characteristics of a dual-field Stanford technique to a customized single-field Stanford technique for total skin electron therapy","volume":"59","author":"Chen","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2019.07.018_bib49","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/0360-3016(90)90075-U","article-title":"Development of total-skin electron therapy at two energies","volume":"18","author":"Cox","year":"1990","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2019.07.018_bib50","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1396-0296.2003.01647.x","article-title":"Mycosis fungoides: radiation therapy","volume":"16","author":"Hoppe","year":"2003","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.clon.2019.07.018_bib51","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.rpor.2013.05.002","article-title":"Institutional experience with a rotational total skin electron irradiation (RTSEI) technique \u2013 a three decade review (1981\u20132012)","volume":"19","author":"Evans","year":"2014","journal-title":"Rep Pract Oncol Radiother"},{"key":"10.1016\/j.clon.2019.07.018_bib52","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.rpor.2013.07.002","article-title":"Technical and dosimetric aspects of the total skin electron beam technique implemented at Heidelberg University Hospital","volume":"19","author":"Hensley","year":"2014","journal-title":"Rep Pract Oncol Radiother"},{"key":"10.1016\/j.clon.2019.07.018_bib53","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1259\/0007-1285-57-678-501","article-title":"Clinical aspects of a rotational total skin electron irradiation","volume":"57","author":"Kim","year":"1984","journal-title":"Br J Radiol"},{"key":"10.1016\/j.clon.2019.07.018_bib54","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1148\/130.2.493","article-title":"Total-body superficial electron-beam therapy using a multiple-field pendulum-arc technique","volume":"130","author":"Sewchand","year":"1979","journal-title":"Radiology"},{"key":"10.1016\/j.clon.2019.07.018_bib55","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0360-3016(97)00141-7","article-title":"Lying-on position of total skin electron therapy","volume":"39","author":"Wu","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2019.07.018_bib56","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1067\/mjd.2002.123482","article-title":"Total skin electron radiation in the management of mycosis fungoides: consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group","volume":"47","author":"Jones","year":"2002","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.clon.2019.07.018_bib57","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s13014-018-1100-4","article-title":"Light and shadows of a new technique: is photon total-skin irradiation using helical IMRT feasible, less complex and as toxic as the electrons one?","volume":"13","author":"Buglione","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.clon.2019.07.018_bib58","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13014-019-1220-5","article-title":"Simultaneous integrated boost with helical arc radiotherapy of total skin (HEARTS) to treat cutaneous manifestations of advanced, therapy-refractory cutaneous lymphoma and leukemia \u2013 dosimetry comparison of different regimens and clinical application","volume":"14","author":"Hsieh","year":"2019","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.clon.2019.07.018_bib59","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/0360-3016(77)90182-1","article-title":"The rationale for curative radiotherapy in mycosis fungoides","volume":"2","author":"Hoppe","year":"1977","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2019.07.018_bib60","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jaad.2014.10.014","article-title":"Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: results of a pooled analysis from 3 phase-II clinical trials","volume":"72","author":"Hoppe","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.clon.2019.07.018_bib61","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2133.2011.10670.x","article-title":"Low-dose total skin electron beam therapy as a debulking agent for cutaneous T-cell lymphoma: an open-label prospective phase II study","volume":"166","author":"Kamstrup","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clon.2019.07.018_bib62","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S0190-9622(96)90442-9","article-title":"Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders","volume":"34","author":"Vonderheid","year":"1996","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.clon.2019.07.018_bib63","first-page":"581","article-title":"Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma","volume":"137","author":"Duvic","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clon.2019.07.018_bib64","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II\u2013III trial results","volume":"19","author":"Duvic","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2019.07.018_bib65","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1365-2133.2007.07975.x","article-title":"The optimal use of bexarotene in cutaneous T-cell lymphoma","volume":"157","author":"Gniadecki","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clon.2019.07.018_bib66","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.1990.8.1.155","article-title":"Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sezary syndrome","volume":"8","author":"Kohn","year":"1990","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2019.07.018_bib67","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0190-9622(89)70049-9","article-title":"Interferon alfa-2a in the treatment of cutaneous T cell lymphoma","volume":"20","author":"Olsen","year":"1989","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.clon.2019.07.018_bib68","first-page":"3578","article-title":"Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II","volume":"92","author":"Stadler","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.clon.2019.07.018_bib69","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1002\/cncr.22596","article-title":"Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma","volume":"109","author":"Straus","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2019.07.018_bib70","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1056\/NEJM198702053160603","article-title":"Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results","volume":"316","author":"Edelson","year":"1987","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl. 1","key":"10.1016\/j.clon.2019.07.018_bib71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jdv.12311","article-title":"Guidelines on the use of extracorporeal photopheresis","volume":"28","author":"Knobler","year":"2014","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clon.2019.07.018_bib72","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/bjh.14537","article-title":"The role of extracorporeal photopheresis in the management of cutaneous T-cell lymphoma, graft-versus-host disease and organ transplant rejection: a consensus statement update from the UK Photopheresis Society","volume":"177","author":"Alfred","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clon.2019.07.018_bib73","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3109\/10428199809057618","article-title":"Systemic polychemotherapy in the treatment of primary cutaneous lymphomas: a clinical follow-up study of 81 patients treated with COP or CHOP","volume":"31","author":"Fierro","year":"1998","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clon.2019.07.018_bib74","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3816\/CLM.2006.n.039","article-title":"Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma","volume":"7","author":"Duvic","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.clon.2019.07.018_bib75","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1200\/JCO.2000.18.13.2603","article-title":"Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients","volume":"18","author":"Zinzani","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2019.07.018_bib76","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1200\/JCO.2011.39.8065","article-title":"Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012","volume":"30","author":"Dummer","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2019.07.018_bib77","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1001\/archderm.144.6.727","article-title":"Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sezary syndrome","volume":"144","author":"Quereux","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clon.2019.07.018_bib78","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/cncr.11593","article-title":"Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma","volume":"98","author":"Wollina","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2019.07.018_bib79","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)","volume":"109","author":"Duvic","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clon.2019.07.018_bib80","doi-asserted-by":"crossref","first-page":"412","DOI":"10.3816\/CLM.2009.n.082","article-title":"Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma","volume":"9","author":"Duvic","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.clon.2019.07.018_bib81","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2019.07.018_bib82","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","article-title":"Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma","volume":"27","author":"Piekarz","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2019.07.018_bib83","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma","volume":"28","author":"Whittaker","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2019.07.018_bib84","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.clml.2012.01.010","article-title":"Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study","volume":"12","author":"Foss","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clon.2019.07.018_bib85","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1182\/blood-2011-11-390211","article-title":"Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"119","author":"Horwitz","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clon.2019.07.018_bib86","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.clml.2014.01.010","article-title":"Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed\/refractory mycosis fungoides","volume":"14","author":"Talpur","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clon.2019.07.018_bib87","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1001\/archdermatol.2009.23","article-title":"Treatment of cutaneous B-cell lymphoma, leg type, with age-adapted combinations of chemotherapies and rituximab","volume":"145","author":"Grange","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clon.2019.07.018_bib88","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1001\/jamadermatol.2013.7452","article-title":"Improvement of survival in patients with primary cutaneous diffuse large B-cell lymphoma, leg type, in France","volume":"150","author":"Grange","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clon.2019.07.018_bib89","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1684\/ejd.2009.0688","article-title":"Primary cutaneous large B-cell lymphoma, leg type, successfully treated with rituximab plus chemotherapy","volume":"19","author":"Posada","year":"2009","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.clon.2019.07.018_bib90","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.jaad.2008.08.005","article-title":"Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab","volume":"59","author":"Morales","year":"2008","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.clon.2019.07.018_bib91","first-page":"319","article-title":"Intralesional anti-CD20 antibody for low-grade primary cutaneous B-cell lymphoma: adverse reactions correlate with favorable clinical outcome","volume":"15","author":"Eberle","year":"2017","journal-title":"J\u00a0Dtsch Dermatol Ges"},{"key":"10.1016\/j.clon.2019.07.018_bib92","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/j.1365-2133.2006.07523.x","article-title":"Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases","volume":"155","author":"Kerl","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clon.2019.07.018_bib93","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1365-2133.2012.10902.x","article-title":"Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: an epidemiological observational multicentre study. The Spanish Working Group on Cutaneous Lymphoma","volume":"167","author":"Penate","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clon.2019.07.018_bib94","doi-asserted-by":"crossref","first-page":"396","DOI":"10.2340\/00015555-2270","article-title":"Intralesional rituximab treatment for primary cutaneous B-cell lymphoma: nine Finnish cases","volume":"96","author":"Vakeva","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.clon.2019.07.018_bib95","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1200\/JCO.2014.60.3787","article-title":"Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis","volume":"33","author":"Duvic","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2019.07.018_bib96","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1200\/JCO.2014.60.3969","article-title":"Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and Sezary syndrome with variable CD30 expression level: a multi-institution collaborative project","volume":"33","author":"Kim","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2019.07.018_bib97","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2019.07.018_bib98","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2019.07.018_bib99","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-016-0201-6","article-title":"Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders","volume":"4","author":"Phillips","year":"2016","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.clon.2019.07.018_bib100","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1158\/2326-6066.CIR-17-0270","article-title":"Primary T cells from cutaneous T-cell lymphoma skin explants display an exhausted immune checkpoint profile","volume":"6","author":"Querfeld","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.clon.2019.07.018_bib101","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/PAS.0000000000000983","article-title":"PD-L1 and PD-L2 are differentially expressed by macrophages or tumor cells in primary cutaneous diffuse large B-cell lymphoma, leg type","volume":"42","author":"Menguy","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clon.2019.07.018_bib102","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1097\/PAS.0000000000000851","article-title":"Tumor microenvironment and checkpoint molecules in primary cutaneous diffuse large B-cell lymphoma new therapeutic targets","volume":"41","author":"Mitteldorf","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clon.2019.07.018_bib103","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.jid.2018.04.038","article-title":"Genomic analyses identify recurrent alterations in immune evasion genes in diffuse large B-cell lymphoma, leg type","volume":"138","author":"Zhou","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.clon.2019.07.018_bib104","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/sj.bmt.1705968","article-title":"Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma","volume":"41","author":"Duarte","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clon.2019.07.018_bib105","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3324\/haematol.2013.098145","article-title":"Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas","volume":"99","author":"de Masson","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.clon.2019.07.018_bib106","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1200\/JCO.2014.57.5597","article-title":"Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sezary syndrome: a European Society for Blood and Marrow Transplantation Lymphoma Working Party extended analysis","volume":"32","author":"Duarte","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2019.07.018_bib107","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1093\/annonc\/mdv473","article-title":"Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution","volume":"26","author":"Hosing","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2019.07.018_bib108","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/bmt.2014.161","article-title":"Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome","volume":"49","author":"Lechowicz","year":"2014","journal-title":"Bone Marrow Transplant"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655519303280?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655519303280?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:47:31Z","timestamp":1760543251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655519303280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":108,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0936655519303280"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2019.07.018","relation":{},"ISSN":["0936-6555"],"issn-type":[{"type":"print","value":"0936-6555"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cutaneous Lymphomas","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2019.07.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}